X
<

Where BD Stands after Its Latest Developments

PART:
1 2 3 4
Part 2
Where BD Stands after Its Latest Developments PART 2 OF 4

Understanding BD’s Recent Stock Performance

BD’s stock performance

On October 5, 2017, Becton, Dickinson, and Company (BDX), or BD, closed the day at $197.25 per share. The stock has a 50-day moving average of $197.25, while its 200-day moving average is $192.35.

BD stock was trading at its 52-week high of $206.63 on July 25, 2017. On December 7, 2016, the stock registered its 52-week low of $161.29 per share.

Understanding BD’s Recent Stock Performance

Interested in BDX? Don't miss the next report.

Receive e-mail alerts for new research on BDX

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

BD released its latest quarterly earnings on August 3, 2017, and the company announced its 3Q17 results on the day. Its revenues came in lower than the Wall Street estimates, which triggered a slight decline in the stock’s price that day, but BD expects to register strong growth in fiscal 2017, with headwinds in 3Q17 not expected to impact future quarters.

BD stock has risen ~19.2% YTD (year-to-date). Over the past six months, the stock has gained 7.6%, but it has fallen 1.4% in the past month.

Peer and industry comparison

In the past 12 months, BD stock has registered a return of ~9.7%, while the S&P 500 Index has gained 17.7% during the same period, and the US medical device sector (IHI) has gained 17.2%.

On October 6, 2017, peers Stryker (SYK), Thermo Fisher Scientific (TMO), and Zimmer Biomet Holdings (ZBH) have gained ~27.4%, ~21.6%, and about -8.3%, respectively, over the past year.

In the next part, we’ll examine BD’s latest developments in diabetes.

X

Please select a profession that best describes you: